Wedbush analyst Yun Zhong has maintained their bullish stance on ASND stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yun Zhong’s rating is based on several key considerations surrounding Ascendis Pharma. Firstly, the recent U.S. launch of Yorvipath in December 2024 is a significant factor, as the therapy’s initial reception and anticipated market positioning against other treatments are crucial to its success. This new treatment offers a promising clinical profile for addressing hypoparathyroidism, an area with limited hormone replacement therapy options until recently.
Moreover, the involvement of Dr. Tamara Vokes, a respected expert in metabolic bone diseases, adds credibility to the potential effectiveness of Yorvipath. Her research and clinical trials in hormone replacement therapies for hypoparathyroidism highlight the unmet medical needs that Ascendis Pharma aims to address. These elements collectively support a positive outlook for Ascendis Pharma, justifying Yun Zhong’s Buy rating.
In another report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $170.00 price target.